Australia's most trusted source of pharma news
Monday, 30 March 2015
Lost Your Access?
Lyrica leads top 20 growth products
In a major change from this time last year, Pfizer's
has become the fastest growing product among the PBS top 20. See the full list.
Chemist Warehouse loses court case
Pharmacy discounter Chemist Warehouse has lost its case against rival chain Direct Chemist Outlet for allegedly misleading consumers.
NZ waits for Sovaldi, Harvoni too
Just like in Australia, Gilead's blockbuster hep C treatments remain unfunded in NZ but PHARMAC won't give a time frame for a decision.
Consumers' health spend must grow
Australian consumers will need to shoulder more of the healthcare spending burden as population ages and expenses grow says Frost & Sullivan.
R&D funding reports could go
Mandatory reporting of R&D funding to the Department of Health when drug patents are granted extensions of term could soon be scrapped.
New MD for iNova/Valeant
Valeant-owned iNova has announced its choice for the new role of Managing Director Australia and New Zealand.
Huge growth rebound on PBS
This time last year, most of the top 20 originators were in growth decline but the latest PBS numbers show a startling 12 month turnaround.
Allergan silent on Actavis jobs
Allergan has declined to reveal the number of jobs that will go as a result of Actavis walking away from the generics business in Australia.
Aust could be denied biosimilars
Australia's biosimilar pathway is still not clear and if makers are forced to market by brand, we could miss out altogether says GMiA CEO Belinda Wood.
First 'Novartis/GSK' cancer listing
The oncology asset swap between GSK and Novartis has had its first market effect in Australia with the companies jointly announcing the PBS listing of
Aust market finds unlikely balance
Despite steady decline in the value of F2 medicines other forces, including hospital sales, are working to balance the Australian pharma market says IMS.
Lemtrada PBS listed despite rejection
Sanofi's MS drug
will be listed on April 1 despite a November 2014 rejection by the PBAC of a submission seeking a recommendation change.
AbbVie boss: HCV patients holding off
AbbVie GM Kirsten O'Doherty says hep C patients are now delaying treatment in hope of newer drugs and reveals a forthcoming PBAC submission.
DUSC to target ADHD drugs
DUSC has specified ADHD drugs as its next target and passed details of higher than expectd
use on to the PBAC.
Aussies trawl net before seeing Drs
: What proportion of Aussies trawls the net before going to the doctor? It's probably more than you think.
Let TGA decide on biosims: MA
MA CEO Tim James responds to GMiA's Belinda Wood in the debate over the future of biosimilar regulation and reimbursement.
Capped PBS a bad idea says study
New research finds NZ lags Australia in meds access and warns against any capping of the PBS as recommended by last year's Commission of Audit.
Sigma's $200m chemist co-op deal
Wholesaler Sigma Pharmaceutical has signed a $200 million, five-year deal with chemist co-op SmarterPharm.
Call for more painkiller controls
Increasing concerns over abuse of OTC analgesics prompts the Pharmaceutical Society to release a position paper on minimising harms from inappropriate use.
MSD hails melanoma gain
As the industry awaits a PBAC decision on MSD's
the company says it has beaten rival
in a head-to-head study.
Cancer inquiry report delayed again
The reporting date for the Senate inquiry into the availability of new, innovative and specialist cancer drugs has been pushed back by another month.
MA rejects blame for slow access
MA says that even if commercial delays are taken into account, Australia is still 10 to 12 months behind in granting access to new medicines.
Generics and originators face off in biosim battle
Who will dominate the biosim market? Established generics makers and originators with biosimilars in the pipeline are set to battle for Australia's developing market.
Funding new gen cancer drugs demands co-operation
Professor John Zalcberg says industry, government, clinicians and consumers must co-operate to ensure access to new generation of cancer medications.
AZ joins COPD rush, Novo wins in weight loss
AZ plans to join the COPD rush following encouraging phase III results for investigational drug PT003, while Novo wins EU approval for weight loss brand of
Important new approval for Roche
Roche has won Australian registration for
, the subcutaneous formulation of its breast and gastric cancer drug Herceptin while Celgene's
is also new to the register.
How to grab control of your pharma career
Lots of us start the year with career goals but staying on track day to day can be a challenge. Here are some tips for keeping your long term future in the frame.
Events & Conferences
© 2003 - 2015 Lush Media
Pharma in Focus
Jolly Good Design